nafamostat has been researched along with Hyperlipoproteinemia Type II in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kojima, S | 1 |
| Ogi, M | 1 |
| Yoshitomi, Y | 1 |
| Kuramochi, M | 1 |
| Ikeda, J | 1 |
| Naganawa, M | 1 |
| Hatakeyama, H | 1 |
1 other study available for nafamostat and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis.
Topics: 6-Ketoprostaglandin F1 alpha; Anticoagulants; Benzamidines; Blood Component Removal; Bradykinin; Cyc | 1997 |